pyrazines has been researched along with Systemic Inflammatory Response Syndrome in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Bayrakci, B; Cengiz, AB; Gülhan, B; Gürlevik, SL; Kesici, S; Kurt Sukur, ED; Oygar, PD; Ozen, S; Ozsurekci, Y; Topaloglu, R | 1 |
| David, CS; Patel, R; Rajagopalan, G; Theuer, JE; Tilahun, AY | 1 |
| Cao-Danh, H; Cowan, DB; del Nido, PJ; Friehs, I; Glynn, P; Ibrahim, AE; McGowan, FX; Poutias, D; Takeuchi, K | 1 |
1 trial(s) available for pyrazines and Systemic Inflammatory Response Syndrome
| Article | Year |
|---|---|
Favipiravir use in children with COVID-19 and acute kidney injury: is it safe?
Topics: Acute Kidney Injury; Adenosine Monophosphate; Adolescent; Alanine; Amides; Child; COVID-19; COVID-19 Drug Treatment; Creatinine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Glomerular Filtration Rate; Humans; Male; Pyrazines; Renal Elimination; SARS-CoV-2; Systemic Inflammatory Response Syndrome; Treatment Outcome | 2021 |
2 other study(ies) available for pyrazines and Systemic Inflammatory Response Syndrome
| Article | Year |
|---|---|
Detrimental effect of the proteasome inhibitor, bortezomib in bacterial superantigen- and lipopolysaccharide-induced systemic inflammation.
Topics: Acetylcysteine; Animals; Apoptosis; Boronic Acids; Bortezomib; Cysteine Proteinase Inhibitors; Cytokines; HLA-DR3 Antigen; Lipopolysaccharides; Liver; Mice; Mice, Transgenic; NF-kappa B; Proteasome Inhibitors; Pyrazines; Superantigens; Systemic Inflammatory Response Syndrome | 2010 |
Vesnarinone and amrinone reduce the systemic inflammatory response syndrome.
Topics: Adjuvants, Immunologic; Amrinone; Animals; Drug Evaluation, Preclinical; Endotoxemia; Endotoxins; Heart; Inflammation Mediators; Interleukin-1; Lung; Myocardium; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Phosphodiesterase Inhibitors; Pyrazines; Quinolines; Rabbits; Salmonella typhimurium; Systemic Inflammatory Response Syndrome; Time Factors; Tumor Necrosis Factor-alpha | 1999 |